Opinion

Video

Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

Author(s):

Nihar Desai, MD, MPH,Nathan Wong, PhD

Experts discuss the evidence supporting the continuous relationship between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD), as recognized by the National Lipid Association, and explore how Lp(a) levels may change throughout a person’s lifetime or in response to lifestyle factors.

Video content above is prompted by the following:

  • Historically, Lp(a) levels of at least 125 nmol/L (or 50 mg/dL) have been considered elevated. However, the National Lipid Association—or NLA—now recognizes the relationship between Lp(a) and ASCVD to be continuous. Could you speak to the evidence supporting this conclusion?
  • How, if at all, do Lp(a) levels change throughout a person’s lifetime or in response to lifestyle factors?
Related Videos
4 experts are featured in this series.
1 expert is featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
Related Content
One's ZIP code can greatly influence care access | image credit: Syda Productions - stock.adobe.com
April 18th 2025

"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health

Kyle Munz Antoine Keller, MD, FACC, FACS
Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Managed Care Cast
May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi
In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
ACC.25
April 4th 2025

High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment

Giuliana Grossi Christian Ruff, MD John Buse, MD, PhD Marc P. Bonaca, MD, MPH Marc Humbert, MD, PhD Jawad Haider Butt, MD, PhD Siddharth M. Patel, MD, MPH
Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Managed care cast logo.
May 10th 2022

For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management

On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Nathan Wong, PhD
March 24th 2025

Raising Awareness of Lp(a) to Improve Heart Disease Treatment Approaches

Kyle Munz Nathan Wong, PhD
Lipoprotein(a) [Lp(a)] plays a key role in assessing cardiovascular risk, making awareness efforts equally essential for prevention and early intervention.
FDA Approval | image credit: PKartstudio - stock.adobe.com
March 21st 2025

FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions

Kyle Munz
In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo